DCPH — Deciphera Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $2.21bn
- $1.94bn
- $163.36m
Brief: Deciphera Pharmaceuticals Reports Q4 product revenues $32.88 million
Brief: Deciphera Pharmaceuticals Announces Fourth Quarter And Full Year 2022 Financial Results
Deciphera Pharmaceuticals Inc expected to post a loss of 56 cents a share - Earnings Preview
Brief: Deciphera Pharmaceuticals Plans To Initiate Insight Pivotal Phase 3 Clinical Study In Second Half Of 2023
U.S. STOCKS ON THE MOVE-Eli Lilly, Tesla, Kohl's, Ally Financial
U.S. STOCKS ON THE MOVE-Netflix, PagerDuty, Proterra
Deciphera Pharma rebounds after pricing equity offering
Brief: Deciphera Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
Deciphera Pharma tumbles on stock offering plans
Brief: Deciphera Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Deciphera Pharma drops on planned $125 mln stock offering
U.S. RESEARCH ROUNDUP- Humana, JP Morgan, Voya Financial
U.S. RESEARCH ROUNDUP- Apollo Global Management, Microsoft, ServiceNow
Brief: Deciphera Pharmaceuticals Announces Planned 2023 Corporate Milestones
Brief: Deciphera Pharmaceuticals Announces Results From CtDNA Analysis From Intrigue Phase 3 Clinical Study
Deciphera Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Deciphera Pharmaceuticals Inc Announces Third Quarter 2022 Financial Results
Deciphera Pharmaceuticals Inc expected to post a loss of 58 cents a share - Earnings Preview
Deciphera Pharmaceuticals Inc expected to post a loss of 58 cents a share - Earnings Preview